Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human, immunization, disease outbreaks - vaccines, - active immunisation against h5n1 subtype of influenza a virus., this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain., prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.,

RESPISURE MH/HPS VACCINE (INACTIVATED) Αυστραλία - Αγγλικά - APVMA (Australian Pesticides and Veterinary Medicines Authority)

respisure mh/hps vaccine (inactivated)

zoetis - vaccine - mycoplasma hyopneum.+vaccine - glassers - parenteral liquid/solution/suspension - vaccine - pigs | boar | gilt | piglet | sow | swine - glassers disease | growth suppression | haemophilus parasuis serovar 13 | haemophilus parasuis serovar 4 | haemophilus parasuis serovar 5 | lung lesions | mycoplasma hyopneumoniae | polyserositis | respiratory disease | reduction of lung lesions | respiratory disease | swine enzootic pneumonia

PROTECH C2I CANINE CORONAVIRUS & LEPTOSPIRA COPENHAGENI KILLED VACCINE Αυστραλία - Αγγλικά - APVMA (Australian Pesticides and Veterinary Medicines Authority)

protech c2i canine coronavirus & leptospira copenhageni killed vaccine

boehringer ingelheim animal health australia pty. ltd. - leptospira icterohaemorrhagiae antigen; canine coronavirus vaccine - antigen - misc. vaccines or anti sera - leptospira icterohaemorrhagiae antigen vaccine-antigen active 1.0 rp; canine coronavirus vaccine - antigen vaccine-viral active 1.62 rp - immunotherapy - dog - over 6 weeks old - canine adenovirus - type 1 | canine adenovirus - type 2 | canine coronavirus | canine distemper | canine parainfluenza | canine parvovirus | leptospira icterohaemorrhagiae | parvovirus

WEBSTERS BURSAVAC K INFECTIOUS BURSAL DISEASE VACCINE (OIL ADJUVANTED INACTIVATED V877 STRAIN VIRUS) Αυστραλία - Αγγλικά - APVMA (Australian Pesticides and Veterinary Medicines Authority)

websters bursavac k infectious bursal disease vaccine (oil adjuvanted inactivated v877 strain virus)

zoetis australia pty ltd - infectious bursal disease virus (ibd) strain v877 - misc. vaccines or anti sera - infectious bursal disease virus (ibd) strain v877 vaccine-viral active 0.0 p - immunotherapy - fowl - infectious bursal disease | vaccine | bursal disease | equine rotavirus

TYPHIM VI SOLUTION Καναδάς - Αγγλικά - Health Canada

typhim vi solution

sanofi pasteur limited - salmonella typhi vi capsular polysaccharide vaccine - solution - 25mcg - salmonella typhi vi capsular polysaccharide vaccine 25mcg - vaccines

TYPHERIX LIQUID Καναδάς - Αγγλικά - Health Canada

typherix liquid

glaxosmithkline inc - salmonella typhi vi capsular polysaccharide vaccine - liquid - 25mcg - salmonella typhi vi capsular polysaccharide vaccine 25mcg - vaccines

VIVOTIF-B capsule Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

vivotif-b capsule

rebel distributors corp - salmonella enterica subsp. enterica serovar typhi (unii: 760t5r8b3o) (salmonella enterica subsp. enterica serovar typhi - unii:760t5r8b3o) - salmonella enterica subsp. enterica serovar typhi 2 [cfu] - vivotif (typhoid vaccine live oral ty21a) is indicated for immunization of adults and children greater than 6 years of age against disease caused by salmonella typhi . routine typhoid vaccination is not recommended in the united states of america. selective immunization against typhoid fever is recommended for the following groups: 1) travelers to areas in which there is a recognized risk of exposure to s. typhi , 2) persons with intimate exposure (e.g. household contact) to a s. typhi carrier, and 3) microbiology laboratorians who work frequently with s. typhi (7). there is no evidence to support the use of typhoid vaccine to control common source outbreaks, disease following natural disasters or in persons attending rural summer camps. not all recipients of vivotif will be fully protected against typhoid fever. vaccinated individuals should continue to take personal precautions against exposure to typhoid organisms. the vaccine will not afford protection against species of salmonella other than salmonella